Archived 1 month ago from Global ResearchBREAKING: BioNTech mRNA Cancer “Vaccine” Trial Terminated Over Alarming Mortality Signal
BioNTech has abruptly terminated a Phase 2 trial of its experimental personalized mRNA cancer “vaccine” after an independent safety board identified an alarming imbalance in overall survival between the treatment groups. The trial, known as BNT122-01 (NCT04486378), enrolled approximately 327 …
Read More